BMRN Stock Analysis: Biomarin Pharmaceutical | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 11.879m USD | 12M Return: 12.3% | US09061G1013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 98.0M
EPS Trend: 63.6%
Qual. Beats: 0
Rev. Trend: 99.1%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioMarin Pharmaceutical Inc. (BMRN) is a U.S.-based biotechnology company founded in 1996 and headquartered in San Rafael, California, that develops and commercializes therapies for life-threatening rare diseases and medical conditions. It markets several specialty treatments, including VIMIZIM (MPS IV type A), VOXZOGO (achondroplasia), NAGLAZYME (MPS VI), PALYNZIQ (phenylketonuria), BRINEURA (Batten disease), ALDURAZYME, and KUVAN. Its pipeline includes BMN 333 for growth disorders and BMN 351 for Duchenne muscular dystrophy. The company sells globally-across the U.S., Europe, Latin America, the Middle East, and Asia Pacific-through specialty pharmacies, hospitals, government agencies, distributors, and pharmaceutical wholesalers, and holds a license and collaboration agreement with Ares Trading S.A.
As a large-cap biotechnology company listed on NASDAQ since 1999, BioMarin operates within the orphan drug business model, focusing on treatments for small patient populations with limited therapeutic alternatives. This specialization typically allows for extended market exclusivity under orphan drug designations, though it also concentrates revenue among a small number of high-cost specialty therapies.
- VOXZOGO drives top-line growth as achondroplasia launch expands globally
- PALYNZIQ revenue climbs with broader PKU patient uptake and label expansion
- Pipeline catalysts from BMN 333 and BMN 351 shape long-term growth narrative
| Net Income: 73.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -1.27 > 1.0 |
| NWC/Revenue: 67.74% < 20% (prev 101.9%; Δ -34.14% < -1%) |
| CFO/TA 0.09 > 3% & CFO 1.08b > Net Income 73.0m |
| Net Debt (3.34b) to EBITDA (115.1m): 28.99 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (194.1m) vs 12m ago -1.27% < -2% |
| Gross Margin: 75.55% > 18% (prev 79.56%; Δ -4.01% > 0.5%) |
| Asset Turnover: 35.52% > 50% (prev 41.09%; Δ -5.56% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.20 (Total Current Assets 3.97b - Total Current Liabilities 1.66b) / Total Assets 11.7b |
| B: 0.03 (Retained Earnings 304.5m / Total Assets 11.7b) |
| C: 0.01 (EBIT TTM 76.2m / Avg Total Assets 9.59b) |
| D: 1.17 (Book Value of Equity 6.32b / Total Liabilities 5.40b) |
| Altman-Z'' = 2.66 = A |
| DSRI: 1.11 (Receivables 1.06b/855.9m, Revenue 3.41b/3.06b) |
| GMI: 1.05 (GM 79.56% / 75.55%) |
| AQI: 1.64 (AQ_t 0.58 / AQ_t-1 0.35) |
| SGI: 1.11 (Revenue 3.41b / 3.06b) |
| TATA: -0.09 (NI 73.0m - CFO 1.08b) / TA 11.7b) |
| Beneish M = -2.43 (Cap -4..+1) = BBB |
As of August 10, 2026, the stock is trading at USD 63.81 with a total of 4,365,077 shares traded. Over the past week, the price has changed by +6.31%, over one month by +6.40%, over three months by +21.36% and over the past year by +12.34%.
Current recommended Stop Loss: 61.80 (which is 3.1% or 1.2 ATR below the current price).
Biomarin Pharmaceutical has received a consensus analysts rating of 4.34. Therefore, it is recommended to buy BMRN.
- StrongBuy: 16
- Buy: 7
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 87.9 | 37.8% |
P/E Trailing = 42.979
P/E Forward = 12.1065
P/S = 3.6638
P/B = 1.8675
P/EG = 0.7406
Revenue TTM = 3.41b USD
EBIT TTM = 76.2m USD
EBITDA TTM = 115.1m USD
Long Term Debt = 597.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 674.3m USD (from shortTermDebt, last quarter)
Debt = 4.21b USD (from shortLongTermDebtTotal, last quarter) + Leases 9.32m
Net Debt = 3.34b USD (calculated: Debt 4.21b - CCE 874.0m)
Enterprise Value = 15.2b USD (11.9b + Debt 4.21b - CCE 874.0m)
Interest Coverage Ratio = unknown (Ebit TTM 76.2m / Interest Expense TTM 0.0)
EV/FCF = 16.22x (Enterprise Value 15.2b / FCF TTM 937.9m)
FCF Yield = 6.16% (FCF TTM 937.9m / Enterprise Value 15.2b)
FCF Margin = 27.53% (FCF TTM 937.9m / Revenue TTM 3.41b)
Net Margin = 2.14% (Net Income TTM 73.0m / Revenue TTM 3.41b)
Gross Margin = 75.55% ((Revenue TTM 3.41b - Cost of Revenue TTM 833.0m) / Revenue TTM)
Gross Margin QoQ = 79.51% (prev 74.55%)
Tobins Q-Ratio = 1.30 (Enterprise Value 15.2b / Total Assets 11.7b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.21b)
Taxrate = 27.08% (16.6m / 61.4m)
NOPAT = 55.6m (EBIT 76.2m * (1 - 27.08%))
Current Ratio = 2.39 (Total Current Assets 3.97b / Total Current Liabilities 1.66b)
Debt / Equity = 0.67 (Debt 4.21b / totalStockholderEquity, last quarter 6.32b)
Debt / EBITDA = 28.99 (Net Debt 3.34b / EBITDA 115.1m)
Debt / FCF = 3.56 (Net Debt 3.34b / FCF TTM 937.9m)
Total Stockholder Equity = 6.17b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.76% (Net Income 73.0m / Total Assets 11.7b)
RoE = 1.18% (Net Income TTM 73.0m / Total Stockholder Equity 6.17b)
RoCE = 1.13% (EBIT 76.2m / Capital Employed (Equity 6.17b + L.T.Debt 597.2m))
RoIC = 0.53% (NOPAT 55.6m / Invested Capital 10.6b)
WACC = 5.27% (E(11.9b)/V(16.1b) * Re(7.14%) + D(4.21b)/V(16.1b) * Rd(0.0%) * (1-Tc(0.27)))
Discount Rate = 7.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -60.23 | Cagr: -1.15%
[DCF] Terminal Value 77.97% ; FCFF base≈839.3m ; Y1≈962.1m ; Y5≈1.42b
[DCF] Fair Price = 92.98 (EV 21.3b - Net Debt 3.34b = Equity 18.0b / Shares 193.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 63.57 | EPS CAGR: 23.72% | SUE: 0.40 | # QB: 0
Revenue Correlation: 99.11 | Revenue CAGR: 15.02% | SUE: 2.45 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.49 | Chg30d=+0.13% | Revisions=+25% | Analysts=15
EPS current Year (2026-12-31): EPS=4.93 | Chg30d=-0.05% | Revisions=+0% | GrowthEPS=+56.6% | GrowthRev=+20.2%
EPS next Year (2027-12-31): EPS=6.39 | Chg30d=-1.07% | Revisions=-25% | GrowthEPS=+29.6% | GrowthRev=+14.3%
[Analyst] Revisions Ratio: +0% (up=2, down=2)